CENTRAL TRUST Co cut its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) by 2.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,681 shares of the financial services provider’s stock after selling 459 shares during the quarter. CENTRAL TRUST Co’s holdings in iShares Biotechnology ETF were worth $2,068,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Apollon Wealth Management LLC raised its stake in shares of iShares Biotechnology ETF by 0.8% during the 3rd quarter. Apollon Wealth Management LLC now owns 10,445 shares of the financial services provider’s stock worth $1,222,000 after purchasing an additional 83 shares in the last quarter. Hudock Inc. lifted its stake in iShares Biotechnology ETF by 0.9% in the 3rd quarter. Hudock Inc. now owns 9,623 shares of the financial services provider’s stock valued at $1,125,000 after purchasing an additional 84 shares during the last quarter. Personal Capital Advisors Corp grew its holdings in iShares Biotechnology ETF by 3.2% during the third quarter. Personal Capital Advisors Corp now owns 2,877 shares of the financial services provider’s stock worth $336,000 after purchasing an additional 88 shares during the period. Patriot Financial Group Insurance Agency LLC increased its position in iShares Biotechnology ETF by 1.5% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 5,868 shares of the financial services provider’s stock worth $686,000 after buying an additional 89 shares during the last quarter. Finally, Synovus Financial Corp raised its stake in iShares Biotechnology ETF by 0.7% in the second quarter. Synovus Financial Corp now owns 12,862 shares of the financial services provider’s stock valued at $1,514,000 after buying an additional 94 shares during the period. Institutional investors and hedge funds own 58.02% of the company’s stock.
iShares Biotechnology ETF Stock Down 0.7 %
Shares of iShares Biotechnology ETF stock opened at $126.06 on Thursday. The business has a fifty day simple moving average of $132.33 and a two-hundred day simple moving average of $128.95. iShares Biotechnology ETF has a 1 year low of $104.29 and a 1 year high of $138.74.
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
- Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Get Rating).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.